Literature DB >> 26464586

Newborn bloodspot screening policy framework for Australia.

Peter O'Leary1, Susannah Maxwell1.   

Abstract

BACKGROUND: The aim of newborn bloodspot screening (NBS) is to identify rare genetic and non-genetic conditions in children soon after birth in order to commence therapies that prevent the development of progressive, serious, and irreversible disabilities. Universal NBS programmes have been implemented in most countries, with minor adaptations to target conditions most relevant to the local healthcare environment. AIMS: In this article, we describe the initiatives of international and Australian governments to develop policies to address the expansion of NBS in their healthcare systems.
METHODS: We have reviewed published public policies and literature to formulate recommendations based on clinical, social, legal, and ethical principles to inform a national governance and policy framework for Australia.
RESULTS: Australian policy makers have been slow to develop a coordinated plan. While the experience from other governments can guide our national policy, there are specific areas that require further consideration by Australian health experts. Key reforms involve the separation of policy and operational activities, multidisciplinary decision-making and oversight by the Australian Health Ministers' Advisory Council for policy direction.
CONCLUSION: A formal national policy framework will guide the coordination of NBS services that can adapt to the needs of Australian children and families.

Entities:  

Keywords:  Newborn screening; genetics; health technology assessment; policy

Year:  2015        PMID: 26464586      PMCID: PMC4592945          DOI: 10.4066/AMJ.2015.2482

Source DB:  PubMed          Journal:  Australas Med J        ISSN: 1836-1935


  26 in total

1.  Newborn screening and maternal diagnosis: rethinking family benefit.

Authors:  Mara Buchbinder; Stefan Timmermans
Journal:  Soc Sci Med       Date:  2011-07-27       Impact factor: 4.634

2.  Evidence based policy making.

Authors:  J A Muir Gray
Journal:  BMJ       Date:  2004-10-30

3.  Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival.

Authors:  Laurie A Myers; Dhavalkumar D Patel; Jennifer M Puck; Rebecca H Buckley
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

4.  The case for newborn screening for congenital adrenal hyperplasia in Australia.

Authors:  Garry L Warne; Katrina L Armstrong; Thomas A Faunce; Bridget M Wilcken; Avihu Boneh; Elizabeth Geelhoed; Maria E Craig
Journal:  Med J Aust       Date:  2010-01-18       Impact factor: 7.738

5.  Impact of new screening technologies: should we screen and does phenotype influence this decision?

Authors:  James Robert Bonham
Journal:  J Inherit Metab Dis       Date:  2013-03-19       Impact factor: 4.982

6.  Newborn bloodspot screening: setting the Australian national policy agenda.

Authors:  Susannah J Maxwell; Peter O'Leary
Journal:  Med J Aust       Date:  2014-02-17       Impact factor: 7.738

7.  Human Genetics Society of Australasia position statement: population-based carrier screening for cystic fibrosis.

Authors:  Martin B Delatycki; Jo Burke; Louise Christie; Felicity Collins; Michael Gabbett; Peter George; Eric Haan; Liane Ioannou; Nicole Martin; Fiona McKenzie; Peter O'Leary; Nicole Scoble-Williams; Gillian Turner; John Massie
Journal:  Twin Res Hum Genet       Date:  2014-12       Impact factor: 1.587

8.  Newborn screening for developmental disabilities: reframing presumptive benefit.

Authors:  Donald B Bailey; Debra Skinner; Steven F Warren
Journal:  Am J Public Health       Date:  2005-09-29       Impact factor: 9.308

9.  Screening newborns for inborn errors of metabolism by tandem mass spectrometry.

Authors:  Bridget Wilcken; Veronica Wiley; Judith Hammond; Kevin Carpenter
Journal:  N Engl J Med       Date:  2003-06-05       Impact factor: 91.245

Review 10.  Achieving the "triple aim" for inborn errors of metabolism: a review of challenges to outcomes research and presentation of a new practice-based evidence framework.

Authors:  Beth K Potter; Pranesh Chakraborty; Jonathan B Kronick; Kumanan Wilson; Doug Coyle; Annette Feigenbaum; Michael T Geraghty; Maria D Karaceper; Julian Little; Aizeddin Mhanni; John J Mitchell; Komudi Siriwardena; Brenda J Wilson; Ania Syrowatka
Journal:  Genet Med       Date:  2012-12-06       Impact factor: 8.822

View more
  2 in total

Review 1.  Is Newborn Screening the Ultimate Strategy to Reduce Diagnostic Delays in Pompe Disease? The Parent and Patient Perspective.

Authors:  Raymond Saich; Renee Brown; Maddy Collicoat; Catherine Jenner; Jenna Primmer; Beverley Clancy; Tarryn Holland; Steven Krinks
Journal:  Int J Neonatal Screen       Date:  2020-01-09

2.  A case for newborn screening for pyridoxine-dependent epilepsy.

Authors:  Curtis R Coughlin; Laura A Tseng; Clara D M van Karnebeek
Journal:  Cold Spring Harb Mol Case Stud       Date:  2022-03-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.